Introduction: Inflammatory response plays a key role in coronavirus disease 2019 (COVID-19) as it has been shown that the resulting cytokine storm increases its severity. Objectives: To investigate the role of procalcitonin (PCT) as a predictor of in-hospital mortality in patients with severe to critical COVID-19. Patients and Methods: In a retrospective cohort study, 150 patients with severe to critical COVID-19 consecutively admitted to the intensive care unit (ICU) were investigated. Patients’ demographics, clinical and laboratory findings, and PCT level were collected upon their admission to the hospital and from the disease outcome data. Results: Of the 150 patients who entered the study, 77 were discharged alive from the hospital. The mean age of the patients was 60.9 ±16.3 years and 51.3% of them were male. The mean PCT level was significantly higher in the deceased patients than in survivors (2.4 ± 3.4 versus 0.7±1.3, P<0.005). The logistic regression analysis indicated that PCT, creatinine and urea levels were independently associated with in-hospital mortality. Conclusion: Serum PCT levels are associated with in-hospital mortality in COVID-19 patients admitted to ICU and could be used as a simple tool to predict adverse outcomes and expedite timely and appropriate interventions.
{"title":"Does procalcitonin play a role as a predictor of in-hospital mortality among COVID-19 patients admitted to intensive care unit?","authors":"Anahita Zakeri, A. Faraone, S. Matin","doi":"10.34172/jpd.2022.9144","DOIUrl":"https://doi.org/10.34172/jpd.2022.9144","url":null,"abstract":"Introduction: Inflammatory response plays a key role in coronavirus disease 2019 (COVID-19) as it has been shown that the resulting cytokine storm increases its severity. Objectives: To investigate the role of procalcitonin (PCT) as a predictor of in-hospital mortality in patients with severe to critical COVID-19. Patients and Methods: In a retrospective cohort study, 150 patients with severe to critical COVID-19 consecutively admitted to the intensive care unit (ICU) were investigated. Patients’ demographics, clinical and laboratory findings, and PCT level were collected upon their admission to the hospital and from the disease outcome data. Results: Of the 150 patients who entered the study, 77 were discharged alive from the hospital. The mean age of the patients was 60.9 ±16.3 years and 51.3% of them were male. The mean PCT level was significantly higher in the deceased patients than in survivors (2.4 ± 3.4 versus 0.7±1.3, P<0.005). The logistic regression analysis indicated that PCT, creatinine and urea levels were independently associated with in-hospital mortality. Conclusion: Serum PCT levels are associated with in-hospital mortality in COVID-19 patients admitted to ICU and could be used as a simple tool to predict adverse outcomes and expedite timely and appropriate interventions.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"73 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86807768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Apoptosis is a programmed cell death commonly investigated in researches. Objectives: According to the lack of a gold standard for definition of apoptosis, we conducted a pilot analysis to propose a new definition for apoptosis based on a previous gene expression data. Materials and Methods: As a secondary analysis, a gene expression data of a vitrification thawing induced model of apoptosis conducted on ten mice ovaries was used. Half of the samples had been treated with selenium. P53, Fas, Bax and Bcl2 were considered as apoptosis related genes. Their +∆CTs were reported. An apoptosis scoring system was designed based on regression analysis. Results: In multiple regression of the genes, the only significant association was for Bcl2 expression for prediction of apoptosis. Then a model was designed consisting of Bcl2 and some interactions that the calculated amount of its formula was considered as the scoring system (R2 = 0.989, P (>F) <0.001, Root mean square deviation = 0.082). Bax/Bcl2 ratio showed an acceptable goodness of fit for prediction of this score (R2 = 0.845, P (>F) <0.001, root mean square deviation = 0.219). No conclusive result was found for factor analysis. Conclusion: The present study used a simple approach to propose statistical models for apoptosis. A comprehensive criterion should be designed apoptosis and other biological systems to be considered as a gold standard.
细胞凋亡是目前研究较多的一种细胞程序性死亡。由于细胞凋亡的定义缺乏金标准，我们进行了一项先导分析，以先前的基因表达数据为基础提出了细胞凋亡的新定义。材料与方法:利用10只小鼠卵巢玻璃化解冻诱导细胞凋亡模型的基因表达数据进行二次分析。一半的样品用硒处理过。P53、Fas、Bax和Bcl2被认为是凋亡相关基因。报告其+∆ct。基于回归分析设计细胞凋亡评分系统。结果:在基因的多元回归中，唯一与Bcl2表达预测细胞凋亡有显著相关性。然后设计一个由Bcl2和一些相互作用组成的模型，以其公式计算量作为评分系统(R2 = 0.989, P (>F) F) <0.001，均方根偏差= 0.219)。因子分析未见结论性结果。结论:本研究采用一种简单的方法建立了细胞凋亡的统计模型。应该设计一个综合的标准，凋亡和其他生物系统被认为是金标准。
{"title":"A pilot design to propose an apoptosis definition based on gene expression data","authors":"Nasim Beigi Boroujeni, Mandana Beigi Boroujeni","doi":"10.34172/jpd.2022.9135","DOIUrl":"https://doi.org/10.34172/jpd.2022.9135","url":null,"abstract":"Introduction: Apoptosis is a programmed cell death commonly investigated in researches. Objectives: According to the lack of a gold standard for definition of apoptosis, we conducted a pilot analysis to propose a new definition for apoptosis based on a previous gene expression data. Materials and Methods: As a secondary analysis, a gene expression data of a vitrification thawing induced model of apoptosis conducted on ten mice ovaries was used. Half of the samples had been treated with selenium. P53, Fas, Bax and Bcl2 were considered as apoptosis related genes. Their +∆CTs were reported. An apoptosis scoring system was designed based on regression analysis. Results: In multiple regression of the genes, the only significant association was for Bcl2 expression for prediction of apoptosis. Then a model was designed consisting of Bcl2 and some interactions that the calculated amount of its formula was considered as the scoring system (R2 = 0.989, P (>F) <0.001, Root mean square deviation = 0.082). Bax/Bcl2 ratio showed an acceptable goodness of fit for prediction of this score (R2 = 0.845, P (>F) <0.001, root mean square deviation = 0.219). No conclusive result was found for factor analysis. Conclusion: The present study used a simple approach to propose statistical models for apoptosis. A comprehensive criterion should be designed apoptosis and other biological systems to be considered as a gold standard.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76418733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Cardiovascular disease represents the leading cause of death in chronic hemodialysis (HD) patients; in this field, abdominal aortic calcifications (AAC) which represent a predictor of cardiovascular events are associated with cardiovascular morbidity and mortality. Objectives: The purpose of our study is to determine the prevalence and factors associated with AAC. Patients and Methods: This cross-sectional study including 40 chronic HD patients for more than six months having benefited from screening for AAC by profile abdominal x-ray without preparation. The AAC were evaluated according to the Kauppila score (ScK). Demographic, biological and radiological data were collected and then analyzed to assess the prevalence of AAC. Patients were divided into two groups according to ScK, highly calcified (ScK ≥12) and slightly or moderately calcified (ScK <12), in order to determine the associated factors to severe AAC. Results: The mean age was 58 ± 16 years, 55% were women, and the median of HD duration is 82 months. The prevalence of AAC was 65% and the median score of AAC was four. Patients with highly AAC (ScK ≥12) represented 27.5% of population and slightly or moderately AAC (ScK <12) represented 72.5%. The factors associated with severe AAC retained in the univariate analysis were age (P=0.029), phosphoremia (P=0.027), duration of dialysis (P=0.047) and calcemia (P=0.035). Only duration of dialysis (P=0.042), age (P=0.018) and phosphoremia (P=0.044) remained statistically significant in multivariate. Conclusion: AAC are associated with advanced age, long duration of dialysis, and phosphocalcic balance abnormalities. Profile abdominal x-ray without preparation is currently recommended by the KDIGO (kidney disease improving global outcomes) for early detection and follow-up of vascular calcifications on HD, which should be considered for any patient.
{"title":"Risk factors for abdominal aortic calcifications in chronic hemodialysis patients","authors":"M. Errihani, T. Aatif, A. Sobhi, D. el kabbaj","doi":"10.34172/jpd.2022.8134","DOIUrl":"https://doi.org/10.34172/jpd.2022.8134","url":null,"abstract":"Introduction: Cardiovascular disease represents the leading cause of death in chronic hemodialysis (HD) patients; in this field, abdominal aortic calcifications (AAC) which represent a predictor of cardiovascular events are associated with cardiovascular morbidity and mortality. Objectives: The purpose of our study is to determine the prevalence and factors associated with AAC. Patients and Methods: This cross-sectional study including 40 chronic HD patients for more than six months having benefited from screening for AAC by profile abdominal x-ray without preparation. The AAC were evaluated according to the Kauppila score (ScK). Demographic, biological and radiological data were collected and then analyzed to assess the prevalence of AAC. Patients were divided into two groups according to ScK, highly calcified (ScK ≥12) and slightly or moderately calcified (ScK <12), in order to determine the associated factors to severe AAC. Results: The mean age was 58 ± 16 years, 55% were women, and the median of HD duration is 82 months. The prevalence of AAC was 65% and the median score of AAC was four. Patients with highly AAC (ScK ≥12) represented 27.5% of population and slightly or moderately AAC (ScK <12) represented 72.5%. The factors associated with severe AAC retained in the univariate analysis were age (P=0.029), phosphoremia (P=0.027), duration of dialysis (P=0.047) and calcemia (P=0.035). Only duration of dialysis (P=0.042), age (P=0.018) and phosphoremia (P=0.044) remained statistically significant in multivariate. Conclusion: AAC are associated with advanced age, long duration of dialysis, and phosphocalcic balance abnormalities. Profile abdominal x-ray without preparation is currently recommended by the KDIGO (kidney disease improving global outcomes) for early detection and follow-up of vascular calcifications on HD, which should be considered for any patient.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82453076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endogenous antibodies can lead to test interference in streptavidin-biotin based laboratory assays, such as thyroid function tests or parathyroid hormone (PTH) levels. We report about a patient, who presented for thyroid surgery, showing undetectable PTH levels despite normocalcaemia in internally assessed preoperative laboratory work. Previously, anti-streptavidin antibodies were detected in the patient’s blood and normal PTH levels could be measured in a streptavidin-free assay. To our knowledge this is the first reported case of a clinically relevant PTH test interference due to endogenous anti-streptavidin antibodies, thus complicating the evaluation of postoperative hypoparathyroidism.
{"title":"Interference caused by anti-streptavidin antibodies in a parathyroid hormone assay; a case report","authors":"B. Trautz, T. Negele","doi":"10.34172/jpd.2022.6134","DOIUrl":"https://doi.org/10.34172/jpd.2022.6134","url":null,"abstract":"Endogenous antibodies can lead to test interference in streptavidin-biotin based laboratory assays, such as thyroid function tests or parathyroid hormone (PTH) levels. We report about a patient, who presented for thyroid surgery, showing undetectable PTH levels despite normocalcaemia in internally assessed preoperative laboratory work. Previously, anti-streptavidin antibodies were detected in the patient’s blood and normal PTH levels could be measured in a streptavidin-free assay. To our knowledge this is the first reported case of a clinically relevant PTH test interference due to endogenous anti-streptavidin antibodies, thus complicating the evaluation of postoperative hypoparathyroidism.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80676321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nephrolithiasis is a common medical issue worldwide and it has an overall prevalence of 7% in women and 10.5% in men (1). It mainly affects active working age population and has high socioeconomic burden (2). Calcium comprises about 80%-90% of the kidney stones components as calcium oxalate and calcium phosphate, so that applying measures for reducing urine calcium excretion have increasingly been used (3). Calcium is absorbed by both active calcitriol-dependent and passive mechanisms in small bowel depending on the amount of daily consumption, and it ranges between 10% to 70% (4,5). It has been shown that kidney stone formers have higher fractional absorption of calcium in intestine leading to greater urinary calcium excretion (6,7). Multiple large studies have shown that calcium intake has a protective role against kidney stone formation by decreasing absorption of intestinal oxalate and subsequent decline in urine oxalate (8-10). Furthermore, Restriction of calcium intake not only would raise risk of oxalate absorption, it also has detrimental effect on bone mineral density which has already been lost in kidney stone formers (11). Therefore, moderate calcium intake of 800-1200 mg daily, mainly by calcium-rich diet or as supplementation taking with diet, is advocated for stone formers (12). It has been demonstrated that intake of calcium supplements both with and without meal increases urine calcium, but because of binding of dietary oxalate with calcium when it is taken with meal, the amount of intestinal oxalate absorption and its urine secretion declines and the rate of stone formation would not increase (13). Of note, apart from calcium intake in high amounts, several other dietary habits including low fluid intake, small intake of fruits and vegetable, large sodium intake, excessive consumption of diet rich in oxalate, and high meat intake are involved in stone formation (14). Therefore, patients who are taking calcium and vitamin D supplements should be advised to consider the foregoing predisposing factors of stone formation. Also, as several systemic diseases such as diabetes, obesity and hypertension are linked with stone disease (15,16), approaches for managing these conditions Implication for health policy/practice/research/medical education Taking recommended doses of supplemental calcium and vitamin D among nephrolithiasis patients have no significant consequence on kidney stone formation.
{"title":"Administration of calcium and vitamin D supplementation in kidney stone formers","authors":"T. Soleymanian","doi":"10.15171/JPD.2018.23","DOIUrl":"https://doi.org/10.15171/JPD.2018.23","url":null,"abstract":"Nephrolithiasis is a common medical issue worldwide and it has an overall prevalence of 7% in women and 10.5% in men (1). It mainly affects active working age population and has high socioeconomic burden (2). Calcium comprises about 80%-90% of the kidney stones components as calcium oxalate and calcium phosphate, so that applying measures for reducing urine calcium excretion have increasingly been used (3). Calcium is absorbed by both active calcitriol-dependent and passive mechanisms in small bowel depending on the amount of daily consumption, and it ranges between 10% to 70% (4,5). It has been shown that kidney stone formers have higher fractional absorption of calcium in intestine leading to greater urinary calcium excretion (6,7). Multiple large studies have shown that calcium intake has a protective role against kidney stone formation by decreasing absorption of intestinal oxalate and subsequent decline in urine oxalate (8-10). Furthermore, Restriction of calcium intake not only would raise risk of oxalate absorption, it also has detrimental effect on bone mineral density which has already been lost in kidney stone formers (11). Therefore, moderate calcium intake of 800-1200 mg daily, mainly by calcium-rich diet or as supplementation taking with diet, is advocated for stone formers (12). It has been demonstrated that intake of calcium supplements both with and without meal increases urine calcium, but because of binding of dietary oxalate with calcium when it is taken with meal, the amount of intestinal oxalate absorption and its urine secretion declines and the rate of stone formation would not increase (13). Of note, apart from calcium intake in high amounts, several other dietary habits including low fluid intake, small intake of fruits and vegetable, large sodium intake, excessive consumption of diet rich in oxalate, and high meat intake are involved in stone formation (14). Therefore, patients who are taking calcium and vitamin D supplements should be advised to consider the foregoing predisposing factors of stone formation. Also, as several systemic diseases such as diabetes, obesity and hypertension are linked with stone disease (15,16), approaches for managing these conditions Implication for health policy/practice/research/medical education Taking recommended doses of supplemental calcium and vitamin D among nephrolithiasis patients have no significant consequence on kidney stone formation.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"38 1","pages":"74-75"},"PeriodicalIF":0.0,"publicationDate":"2018-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79644167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Secondary hyperparathyroidism, is a matter of concern in hemodialysis patients that cause renal osteodystrophy eventually. Objectives: The objective of the study was to compare the efficacy of cholecalciferol with calcitriol for treating secondary hyperparathyroidism. Materials and Methods: This study is a randomized, controlled study. Around 80 patients with hyperparathyroidism (PTH >300 ρg/ mL) and 25(OH)D level <20 ng/mL were divided into two groups to receive cholecalciferol 50 000 IU/3 times in one week or calcitriol 0.25 μg/daily for 12 weeks. Additionally calcium carbonate 1000-1500 mg/d/tablets is prescribed for both groups. Reduction of parathyroid hormone (PTH), changes of plasma albumin-corrected calcium and phosphorus and levels of 25(OH)D were analyzed. Results: Around 40 patients were randomized into each group. At baseline, plasma albumin-corrected calcium, phosphorus and intact PTH and 25(OH)D had no difference between groups. At week 12, intact PTH levels in cholecalciferol and calcitriol groups were 242.38±16.38 ρg/mL and 237.84±13.65 ρg/mL in respectively. Patients who achieved target intact PTH of <300 ρg/mL were 90% in the cholecalciferol and 95% in the calcitriol group (P = 0.447). Serum calcium and phosphorus were not significantly different in both groups. Serum calcium; 9.07±0.36 mg/dL versus 9.00 ± 0.38 mg/dL (P = 0.607), phosphorus; 4.81±0.55 mg/dL versus 4.15 ± 0.42 mg/dL (P = 0.126) in cholecalciferol and calcitriol groups respectively. Furthermore, serum 25(OH)D levels significantly rise in cholecalciferol group. Serum 25(OH)D levels were 62.98 ±21.03 ng/mL in cholecalciferol group and 18.95±22.70 ng/mL in calcitriol group (P < 0.05). Conclusion: cholecalciferol can be administered to control secondary hyperparathyroidism and vitamin D(25OH) deficiency in hemodialysis patients . The two drugs are equally efficacious and lead to similar changes in calcium and phosphorus levels.
{"title":"Cholecalciferol versus calcitriol to manage secondary hyperparathyroidism in hemodialysis patients","authors":"H. Omrani, Ali Daraizade","doi":"10.15171/JPD.2018.27","DOIUrl":"https://doi.org/10.15171/JPD.2018.27","url":null,"abstract":"Introduction: Secondary hyperparathyroidism, is a matter of concern in hemodialysis patients that cause renal osteodystrophy \u0000eventually. \u0000 Objectives: The objective of the study was to compare the efficacy of cholecalciferol with calcitriol for treating secondary \u0000hyperparathyroidism. \u0000 Materials and Methods: This study is a randomized, controlled study. Around 80 patients with hyperparathyroidism (PTH >300 ρg/ \u0000mL) and 25(OH)D level <20 ng/mL were divided into two groups to receive cholecalciferol 50 000 IU/3 times in one week or calcitriol \u00000.25 μg/daily for 12 weeks. Additionally calcium carbonate 1000-1500 mg/d/tablets is prescribed for both groups. Reduction of \u0000parathyroid hormone (PTH), changes of plasma albumin-corrected calcium and phosphorus and levels of 25(OH)D were analyzed. \u0000 Results: Around 40 patients were randomized into each group. At baseline, plasma albumin-corrected calcium, phosphorus and \u0000intact PTH and 25(OH)D had no difference between groups. At week 12, intact PTH levels in cholecalciferol and calcitriol groups \u0000were 242.38±16.38 ρg/mL and 237.84±13.65 ρg/mL in respectively. Patients who achieved target intact PTH of <300 ρg/mL were \u000090% in the cholecalciferol and 95% in the calcitriol group (P = 0.447). Serum calcium and phosphorus were not significantly different \u0000in both groups. Serum calcium; 9.07±0.36 mg/dL versus 9.00 ± 0.38 mg/dL (P = 0.607), phosphorus; 4.81±0.55 mg/dL versus 4.15 ± \u00000.42 mg/dL (P = 0.126) in cholecalciferol and calcitriol groups respectively. Furthermore, serum 25(OH)D levels significantly rise in \u0000cholecalciferol group. Serum 25(OH)D levels were 62.98 ±21.03 ng/mL in cholecalciferol group and 18.95±22.70 ng/mL in calcitriol \u0000group (P < 0.05). \u0000 Conclusion: cholecalciferol can be administered to control secondary hyperparathyroidism and vitamin D(25OH) deficiency in \u0000hemodialysis patients . The two drugs are equally efficacious and lead to similar changes in calcium and phosphorus levels.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"1 1","pages":"87-90"},"PeriodicalIF":0.0,"publicationDate":"2018-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74990900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Aatif, N. E. Esper, P. Morinière, G. Choukroun, A. Fournier
Introduction: Cinacalcet (CNL) suppresses the secretion of parathyroid hormone (PTH). Objective: To consider the effect of CNL administration on achievement of K/DOQITM (Kidney Disease Outcomes Quality Initiative) targets in a group of hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). Patients and Methods: Patients undergoing HD who had initiated CNL enrolled in the study. Data were collected at the baseline and after 12 months. This data consisted of serum calcium (Ca), phosphorus (P), intact PTH (iPTH), proportion of calcium in dialysate, administered doses of CNL and proportion of administered phosphate binders and proportion of patients attaining K/DOQITM targets were gathered. Results: Twenty HD patients enrolled in the study. The proportions of individuals attaining K/DOQITM targets at month 12 were 35% for iPTH, 65% for P, 60% for Ca and 80% for Ca×P product, compared with 0%, 45%, 55% and 50% at the baseline respectively. Around 35% of individuals had attained the combined K/DOQITM targets for Ca, P and iPTH compared with 0% at the starting point. Conclusion: CNL ameliorates attainment of K/DOQITM targets in individuals with SHPT. This result is consistent with findings from other studies.
{"title":"Cinacalcet therapy for achievement of the NKF/K-DOQITM clinical practice guidelines for bone and mineral metabolism in individuals under regular hemodialysis","authors":"T. Aatif, N. E. Esper, P. Morinière, G. Choukroun, A. Fournier","doi":"10.15171/JPD.2018.26","DOIUrl":"https://doi.org/10.15171/JPD.2018.26","url":null,"abstract":"Introduction: Cinacalcet (CNL) suppresses the secretion of parathyroid hormone (PTH). Objective: To consider the effect of CNL administration on achievement of K/DOQITM (Kidney Disease Outcomes Quality Initiative) targets in a group of hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). Patients and Methods: Patients undergoing HD who had initiated CNL enrolled in the study. Data were collected at the baseline and after 12 months. This data consisted of serum calcium (Ca), phosphorus (P), intact PTH (iPTH), proportion of calcium in dialysate, administered doses of CNL and proportion of administered phosphate binders and proportion of patients attaining K/DOQITM targets were gathered. Results: Twenty HD patients enrolled in the study. The proportions of individuals attaining K/DOQITM targets at month 12 were 35% for iPTH, 65% for P, 60% for Ca and 80% for Ca×P product, compared with 0%, 45%, 55% and 50% at the baseline respectively. Around 35% of individuals had attained the combined K/DOQITM targets for Ca, P and iPTH compared with 0% at the starting point. Conclusion: CNL ameliorates attainment of K/DOQITM targets in individuals with SHPT. This result is consistent with findings from other studies.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"121 5 1","pages":"80-86"},"PeriodicalIF":0.0,"publicationDate":"2017-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77297810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seyed Majid Mousavi Movahhed, S. Mousavi, Shokouh Shayanpour, S. A. Halili, Leila Sabetnia
Dear Editor With great interest, we read the recently published article by Zaher Khazaei and colleagues entitled “Vitamin D deficiency in healthy people and its relationship with gender and age” in this journal (1). In this study, they measured serum vitamin D levels in a group of Iranian healthy individuals (102 participants) to evaluate the relationship between serum 25-hydroxy vitamin D with gender and age of participants (1). The results of the study showed that vitamin D level is lower than 20 ng/mL in a significant percentage of healthy individuals (73%) which was considered as vitamin D deficiency. The levels of vitamin D in 18% of participants were between 20.1 to 29.9 ng/mL which were interpreted as a marginal deficiency. Therefore according to the results of this study, only 9% of the healthy individuals had normal vitamin D level and the prevalence of vitamin D deficiency among Iranian healthy individuals was alarming high (1). Similar to the results of Khazaei et al study, the results of other investigations which have performed in some other Asian countries like India and Pakistan showed that majority of people in these countries had severe vitamin D deficiency. As an example, Rasul Khan and colleagues evaluated vitamin D status in patients presenting with a complaint of easy fatigability at a medical outpatient clinic. They showed that 92% of participants had low vitamin D levels. Vitamin D status was in the normal range in only 8% of the patients in the study by Rasul Khan et al (2). A similar percentage (89.3%) of low vitamin D levels was also recorded from Northern Pakistan in the study by Mufti et al (3). Although some data from Saudi Arabia showed that the Saudi population has better vitamin D status as compared to the above studies, however the other data from Saudi Arabia also revealed that majority of the patients had low vitamin D levels (4). As an example, Mirza et al evaluated vitamin D status in individuals with body aches at an outpatient department in Dammam, Saudi Arabia Implication for health policy/practice/research/medical education The prevalence of vitamin D deficiency is alarming high in the world and therefore specialists and general physicians have to be more educated about the causes of vitamin D deficiency.
{"title":"The prevalence of vitamin D deficiency is alarming high","authors":"Seyed Majid Mousavi Movahhed, S. Mousavi, Shokouh Shayanpour, S. A. Halili, Leila Sabetnia","doi":"10.15171/JPD.2018.25","DOIUrl":"https://doi.org/10.15171/JPD.2018.25","url":null,"abstract":"Dear Editor With great interest, we read the recently published article by Zaher Khazaei and colleagues entitled “Vitamin D deficiency in healthy people and its relationship with gender and age” in this journal (1). In this study, they measured serum vitamin D levels in a group of Iranian healthy individuals (102 participants) to evaluate the relationship between serum 25-hydroxy vitamin D with gender and age of participants (1). The results of the study showed that vitamin D level is lower than 20 ng/mL in a significant percentage of healthy individuals (73%) which was considered as vitamin D deficiency. The levels of vitamin D in 18% of participants were between 20.1 to 29.9 ng/mL which were interpreted as a marginal deficiency. Therefore according to the results of this study, only 9% of the healthy individuals had normal vitamin D level and the prevalence of vitamin D deficiency among Iranian healthy individuals was alarming high (1). Similar to the results of Khazaei et al study, the results of other investigations which have performed in some other Asian countries like India and Pakistan showed that majority of people in these countries had severe vitamin D deficiency. As an example, Rasul Khan and colleagues evaluated vitamin D status in patients presenting with a complaint of easy fatigability at a medical outpatient clinic. They showed that 92% of participants had low vitamin D levels. Vitamin D status was in the normal range in only 8% of the patients in the study by Rasul Khan et al (2). A similar percentage (89.3%) of low vitamin D levels was also recorded from Northern Pakistan in the study by Mufti et al (3). Although some data from Saudi Arabia showed that the Saudi population has better vitamin D status as compared to the above studies, however the other data from Saudi Arabia also revealed that majority of the patients had low vitamin D levels (4). As an example, Mirza et al evaluated vitamin D status in individuals with body aches at an outpatient department in Dammam, Saudi Arabia Implication for health policy/practice/research/medical education The prevalence of vitamin D deficiency is alarming high in the world and therefore specialists and general physicians have to be more educated about the causes of vitamin D deficiency.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"7 3 1","pages":"78-79"},"PeriodicalIF":0.0,"publicationDate":"2017-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91065765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Onuigbo, N. Agbasi, A. Khan, Vinay Nijhawan, Zhibin Jiang
We described the unusual presentation of right unilateral facial swelling in a 48-year old end-stage renal disease (ESRD) male patient on maintenance hemodialysis following a failed kidney transplant. This was subsequently confirmed to be secondary to the extrinsic compression of the superior vena cava (SVC) by a large lobulated amorphous extra-osseous right axillary mass lesion that extended into the upper right thoracic outlet. Superior vena cava venogram and balloon angioplasty led to symptomatic relief. The factors involved in the pathogenesis of calciphylaxis are discussed and the available therapeutic options for this rare albeit debilitating disease are reviewed.
{"title":"Superior vena cava syndrome complicating calcific uremic arteriolopathy in an ESRD male patient on maintenance hemodialysis following failed kidney transplantation","authors":"M. Onuigbo, N. Agbasi, A. Khan, Vinay Nijhawan, Zhibin Jiang","doi":"10.15171/JPD.2018.21","DOIUrl":"https://doi.org/10.15171/JPD.2018.21","url":null,"abstract":"We described the unusual presentation of right unilateral facial swelling in a 48-year old end-stage renal disease (ESRD) male patient on maintenance hemodialysis following a failed kidney transplant. This was subsequently confirmed to be secondary to the extrinsic compression of the superior vena cava (SVC) by a large lobulated amorphous extra-osseous right axillary mass lesion that extended into the upper right thoracic outlet. Superior vena cava venogram and balloon angioplasty led to symptomatic relief. The factors involved in the pathogenesis of calciphylaxis are discussed and the available therapeutic options for this rare albeit debilitating disease are reviewed.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"141 1","pages":"68-71"},"PeriodicalIF":0.0,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86596318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Mousavi, F. Hayati, Shokouh Shayanpour, S. A. Halili
Implication for health policy/practice/research/medical educationHypermagnesemia is also not a prominent feature among patients with chronic kidney disease, in the absence of increased magnesium administration, however renal failure mostly at its final stages is most common cause of hypermagnesemia.
{"title":"Magnesium and parathyroid hormone among end-stage renal disease patients","authors":"S. Mousavi, F. Hayati, Shokouh Shayanpour, S. A. Halili","doi":"10.15171/JPD.2018.22","DOIUrl":"https://doi.org/10.15171/JPD.2018.22","url":null,"abstract":"Implication for health policy/practice/research/medical educationHypermagnesemia is also not a prominent feature among patients with chronic kidney disease, in the absence of increased magnesium administration, however renal failure mostly at its final stages is most common cause of hypermagnesemia.","PeriodicalId":16657,"journal":{"name":"Journal of Parathyroid Disease","volume":"50 1","pages":"72-73"},"PeriodicalIF":0.0,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89476149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：